N-Alkylated aziridines are easily-prepared, potent, specific and cell-permeable covalent inhibitors of human β-glucocerebrosidase.
暂无分享,去创建一个
B. Adams | C. P. Phenix | S. Niccoli | A. Esarik | Morshed A. Chowdhury | Simon J. Lees | Brian P. Rempel
[1] D. Krainc,et al. Development of targeted therapies for Parkinson’s disease and related synucleinopathies , 2014, Journal of Lipid Research.
[2] S. Withers,et al. Fluoro-glycosyl acridinones are ultra-sensitive active site titrating agents for retaining β-glycosidases. , 2014, Chemical communications.
[3] S. Stroobants,et al. Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent. , 2014, Nuclear medicine and biology.
[4] G. Halliday,et al. Glucocerebrosidase deficits in sporadic Parkinson disease , 2014, Autophagy.
[5] F. Platt,et al. β-Glucosidase 2 (GBA2) Activity and Imino Sugar Pharmacology* , 2013, The Journal of Biological Chemistry.
[6] Andrew G. Watts,et al. Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity , 2013, Science.
[7] Sylvain Houle,et al. Mapping Human Brain Fatty Acid Amide Hydrolase Activity with PET , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] J. Jiang,et al. Novel activity-based probes for broad-spectrum profiling of retaining β-exoglucosidases in situ and in vivo. , 2012, Angewandte Chemie.
[9] F. Platt,et al. The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. , 2012, The Journal of cell biology.
[10] H. Overkleeft,et al. Tuning the leaving group in 2-deoxy-2-fluoroglucoside results in improved activity-based retaining β-glucosidase probes. , 2012, Chemical communications.
[11] J. Hardy,et al. Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.
[12] Daniel R. Albaugh,et al. Time-Dependent Inhibition and Estimation of CYP3A Clinical Pharmacokinetic Drug-Drug Interactions Using Plated Human Cell Systems , 2012, Drug Metabolism and Disposition.
[13] S. Withers,et al. Tailoring the specificity and reactivity of a mechanism-based inactivator of glucocerebrosidase for potential therapeutic applications. , 2011, Angewandte Chemie.
[14] J. Koricheva,et al. A Meta-Analysis of Predation Risk Effects on Pollinator Behaviour , 2011, PloS one.
[15] D. Chan,et al. Aberrant glycosylation associated with enzymes as cancer biomarkers , 2011, Clinical Proteomics.
[16] G. A. van der Marel,et al. Ultrasensitive in situ visualization of active glucocerebrosidase molecules. , 2010, Nature chemical biology.
[17] E. Sidransky,et al. Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders , 2010, Acta Neuropathologica.
[18] S. Withers,et al. Imaging of enzyme replacement therapy using PET , 2010, Proceedings of the National Academy of Sciences.
[19] P. Mistry,et al. The risk of Parkinson’s disease in type 1 Gaucher disease , 2010, Journal of Inherited Metabolic Disease.
[20] R. Pires,et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. , 2009, The Journal of pediatrics.
[21] S. Withers,et al. Non-Stick Sugars: Synthesis of Difluorosugar Fluorides as Potential Glycosidase Inactivators , 2009 .
[22] A. Baici,et al. 3‐Fluoro‐2,4‐dioxa‐3‐phosphadecalins as Inhibitors of Acetylcholinesterase. A Reappraisal of Kinetic Mechanisms and Diagnostic Methods , 2009, Chemistry & biodiversity.
[23] S. Withers,et al. Covalent inhibitors of glycosidases and their applications in biochemistry and biology. , 2008, Glycobiology.
[24] L. Delbaere,et al. Structural, Functional and Calorimetric Investigation of MosA, a Dihydrodipicolinate Synthase from Sinorhizobium meliloti L5–30, does not Support Involvement in Rhizopine Biosynthesis , 2008, Chembiochem : a European journal of chemical biology.
[25] L. Juillerat-Jeanneret,et al. Glycosylation pathways as drug targets for cancer: glycosidase inhibitors. , 2006, Mini reviews in medicinal chemistry.
[26] M. Piel,et al. Efficient alkali iodide promoted 18F-fluoroethylations with 2-[18F]fluoroethyl tosylate and 1-bromo-2-[18F]fluoroethane , 2003 .
[27] N. Volkow,et al. Strategy for the Formation of Parametric Images under Conditions of Low Injected Radioactivity Applied to PET Studies with the Irreversible Monoamine Oxidase a Tracers [11C]Clorgyline and Deuterium-Substituted [11C]Clorgyline , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[28] N. Volkow,et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] D. M. Ryan,et al. Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.
[30] S. Withers,et al. Conduritol aziridine: a new mechanism-based glucosidase inactivator. , 1989, Biochemical and biophysical research communications.
[31] C. D. Arnett,et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. , 1987, Science.
[32] N. Radin,et al. A revised fluorometric assay for Gaucher's disease using conduritol-beta-epoxide with liver as the source of Beta-glucosidase. , 1980, Clinica chimica acta; international journal of clinical chemistry.
[33] M. Node,et al. Inhibitors against glycosidases as medicines. , 2009, Current topics in medicinal chemistry.